Search Results

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate - technology, announced the appointment of Ulf Grawunder, Ph.D. to its scientific advisory board.

Eternity Biotech, Inc., a biotechnology company dedicated to finding solutions for longer, healthier lives, announced the launch of a crowdfunding campaign on Wefunder to advance its anti-aging product development.

Medigene AG announces that the Company has been issued a patent by the European Patent Office protecting its PD1-41BB costimulatory switch protein technology.

With climbing biotech M&A and IPO activity following the post-pandemic slump, experts offer insights on maximizing value and otherwise capitalizing on exit opportunities.

Araris Biotech AG announced the company will deliver two poster presentations, including one late-breaking poster, at this year’s American Association for Cancer Research Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) announces today that it has selected its lead candidate for MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11 being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.

Big Pharma can’t seem to get enough radiopharmaceutical biotechs. With Lilly, Sanofi and BMS chasing Novartis into the complex space, all eyes are on these specialty biotechs.